JNJ-75276617ALE1001
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants with Acute Leukemia
KURA-KO-MEN-007
Phase I
OPEN TO ACCRUAL
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia
ORYZON-CL04-ORY-1001
Phase I
OPEN TO ACCRUAL
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like Tyrosine Kinase Mutation (FLT3 Mut+): The FRIDA Study